Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

UDI2Claims

Planning a Pilot Project to Transmit Identifiers for Implanted Devices to the Insurance Claim

Zerhouni, Yasmin A. MD*†; Krupka, Dan C. PhD; Graham, Jove PhD§; Landman, Adam MD, MS, MIS, MHS∥††; Li, Angela MPH; Bhatt, Deepak L. MD, MPH**; Nguyen, Louis L. MD, MBA, MPH; Capatch, Kevin MPM§; Concheri, Kevin††; Reich, Amanda J. PhD, MPH*; Wilson, Natalia MD, MPH‡‡; Weissman, Joel S. PhD*

doi: 10.1097/PTS.0000000000000543
Original Article: PDF Only
Buy
PAP

Background In response to problems with the current postmarket surveillance of medical devices, the U.S. Food and Drug Administration mandated device labelers to include a unique device identifier (UDI), composed of a device identifier (DI) and production identifier. Including the DI in insurance claims could be a potent method to monitor implanted devices, yet implementation has lagged because of questions of benefit and operational concerns.

Methods To illustrate the potential benefit of including DIs in claims, rates of 90-day adverse events after implantation using an electronic health record (EHR) were compared with the EHR plus claims, which capture utilization outside that EHR's health system. To explore operations, we planned a pilot project to transmit the DI of implanted devices from the point of care to the claim at two provider/payer pairs.

Results By querying claims plus EHR, estimated rates of patients with potential adverse events were as much as 3.75 times higher. For our pilot, our multistakeholder team identified and resolved the following five challenges: (1) capturing the DI at the point of care; (2) selecting a location for the DI on the claim form; (3) transmitting the DI to the claim form; (4) analyzing the claim forms received by the payer; and (5) verifying the quality of the transmitted information.

Conclusions Including DIs on claims could allow more complete data capture of adverse events for implanted devices than the EHR data. We overcame challenges in transmitting the DI to the claim with attention to planning and multistakeholder involvement.

From the *Center for Surgery and Public Health, Harvard Medical School, Harvard T. Chan School of Public Health, Brigham and Women's Hospital, Boston, Massachusetts;

Department of Surgery, UCSF-East Bay, Oakland, California;

Twin Peaks Group, LLC, Lexington, Massachusetts;

§Care Support Services, Geisinger Health, Danville, Pennsylvania;

Brigham and Women's Hospital;

Blue Cross and Blue Shield of Massachusetts;

**Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School;

††Partners Healthcare, Boston, Massachusetts; and

‡‡College of Health Solutions, Arizona State University, Phoenix, Arizona.

Correspondence: Joel S. Weissman, PhD, 1620 Tremont St, Ste. 4-020, Boston, MA 02120 (e-mail: Jweissman@partners.org).

This study was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (R-1511-32960). The views presented in this publication are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors, or Methodology Committee.

D.L.B. discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (no. Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, PLx Pharma, Takeda.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved